Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Vomiting 5Nausea 5Neoplasms 4Hematologic Neoplasms 4Anorexia 3Multiple Myeloma 2Breast Neoplasms 2Testicular Neoplasms 1Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy 1Prosthesis Failure 1Opioid-Related Disorders 1Nutrition Disorders 1Neoplasms, Plasma Cell 1Gynecologic Cancer 1Cachexia 1Advanced Cancer 1

Interventions

Cyclophosphamide 149Docetaxel 139Paclitaxel 127Trastuzumab 120Tamoxifen 110Capecitabine 104Letrozole 92Epirubicin 79Doxorubicin 70Anastrozole 70exemestane 67Fulvestrant 65Fluorouracil 61Radiotherapy 60pertuzumab 40Gemcitabine 39Carboplatin 38Vinorelbine 34Goserelin 34Bevacizumab 29Zoledronic Acid 28Methotrexate 28Chemotherapy, Adjuvant 28eribulin 27Lapatinib 25ribociclib 24palbociclib 24Drug Therapy 22130-nm albumin-bound paclitaxel 20pegfilgrastim 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Breast Neoplasms × Olanzapine × Clear all
NCT03367572 2025-09-25

Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer

University of Rochester

Phase 3 Completed
1,363 enrolled 20 charts
Breast

Breast Neoplasms

NCT02861859 2020-02-26

Individualised Versus Standard Care for Breast Cancer Patients at High-risk for Chemotherapy-induced Nausea and Vomiting The ILIAD Study

Ottawa Hospital Research Institute

Phase 3 Completed
221 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡